RENALYTIX PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11 GBX | -4.35% |
|
-37.14% | -29.03% |
| 28/06 | ADRs Advance; Connect Biopharma Holdings Climbs 19% | DJ |
| 28/06 | EARNINGS AND TRADING: Thruvision loss widens but Polarean loss narrows | AN |
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Companyâs lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Calendar
29/10/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.11
Average target price
-
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.03% | 22.45M | |
| -34.27% | 14.56B | |
| -54.93% | 2.25B | |
| +15.49% | 1.84B | |
| -14.07% | 1.46B | |
| +21.99% | 1.21B | |
| -35.50% | 804M | |
| +1.25% | 790M | |
| -36.65% | 734M | |
| -28.15% | 597M |
- Stock Market
- Equities
- RENX Stock
- News Renalytix Plc
- HC Wainwright Adjusts Renalytix's Price Target to $10 From $15, Keeps Buy Rating
